Canada: Applying The Rules

Last Updated: March 12 2014
Article by Susan Keri

Several notable developments in Canadian trademark law and practice during the past year are relevant to the pharmaceutical trademark field.

In Canada, the selection of a brand name for a prescription drug must be assessed bearing in mind both regulatory issues handled by Health Canada and trademark registration issues pursuant to the Trademarks Act. If a product name is approved by Health Canada, it does not necessarily follow that the name will be registrable as a trademark; and similarly, if a name is found to be registrable as a trademark, this does not mean that the name will be accepted by Health Canada. Health Canada considers the issue of drug name confusion from a health and safety perspective. By contrast, the selection of a trademark under the Trademarks Act focuses on the likelihood of confusion as to the source of manufacture of the products.

Drug names and Health Canada regulatory approval

The Food and Drug Regulations require a manufacturer to file a new drug submission containing sufficient information and material to enable Health Canada to assess the safety and effectiveness of the drug, including a statement of the brand name. If there are safety concerns, Health Canada may refuse to issue a notice of compliance for new drugs, or a drug identification number for new and existing drugs, both of which are necessary in order to market a pharmaceutical product in Canada.

In an effort to provide clarification regarding the brand-name submission process for proposed drug names, and to reduce the risk of medication errors related to similar drug names, Health Canada drafted a guidance for industry – Drug Name Review: Look-alike Sound-alike (LA/SA) Health Product Names – which came into force in 2006. Pursuant to this guidance, manufacturers are required to submit various materials, data and information to assist Health Canada in assessing the potential for confusion between a new drug name and that of an existing product. However, a review of new drug name submissions since the release of the 2006 guidance revealed significant variations in the amount, type and quality of evidence submitted by manufacturers, largely due to the absence of a clear direction on the process to be followed and the risk assessment methods to employ.

With a view to addressing some of the deficiencies in the 2006 guidance, Health Canada released a draft revised guidance document – Review of Drug Names for Look-alike Sound-alike (LA/SA) Attributes – on February 19 2013. The revised guidance is intended to provide more direction on the process to be followed and the information to be submitted to Health Canada regarding the issue of confusion between a proposed drug name and an existing product.

The revised guidance provides more specific procedures and risk assessment methods for manufacturers to follow when submitting a proposed drug name to Health Canada for approval, including use of a health product name search engine and two simulation tests: psycholinguistic testing and medication use testing.

Consultation on the revised guidance was open from February 19 2013 to April 19 2013. During this time, Health Canada met with individual stakeholders to hear their concerns. Most industry comments focused on the requirement for psycholinguistic testing, which was considered to be too stringent and exacting – particularly when compared to regulations of other countries – with no significant benefits.

In response to industry concerns, Health Canada stated that it would revise the guidance document. Regarding the issue of psycholinguistic testing, it indicated that it may be moved to an appendix to the guidance as an 'optional' test.

The final version of the guidance is expected to take effect in late 2013 or early 2014. Health Canada has proposed at least a one-year transition period during which it will not enforce the new guidance requirements.

Drug names and trademark registration

As noted above, the drug name approval process in Canada is separate and distinct from trademark registration.

In the case of trademark registration, the Trademarks Office must determine whether the co-existence of two similar drug names is likely to cause confusion in the marketplace as to the source of origin of the products. Public health concerns, such as medical risks associated with drug name mistakes, are not, strictly speaking, relevant to the issue of trademark registration.

However, recent Canadian jurisprudence suggests that health and safety concerns may become increasingly relevant when assessing the issue of confusion between drug names for trademark registration purposes. In Sanofi-Aventis v GlaxoSmithKline Biologicals SA ((2010), 89 CPR (4th) 378 (TMOB)), the Trademarks Opposition Board (TMOB) considered the issue of medication errors as a surrounding circumstance contributing to the likelihood of confusion between the trademarks PACIRIX and PLAVIX, and found the marks to be confusing, even though they were associated with different pharmaceutical preparations and end uses.

Non-traditional marks

Colour and shape

In Canada, a trademark consisting of colour applied to the shape of a product is inherently registrable. However, in the pharmaceutical field, there is a high evidential burden on the applicant to establish that the mark serves to distinguish the wares or services of the trademark owner from those of others. An applicant must establish that the colour mark is distinctive in the entire pharmaceutical field, and not only with respect to the specific preparation(s) with which it is associated. Moreover, the applicant must establish that the relevant market – namely, physicians, pharmacists and patients – relates the trademark to a single source of manufacture and uses it to make their prescribing, dispensing or purchasing choices. In the case of colour marks, this is an onerous burden of proof.

The recent TMOB decision in Canadian Generic Pharmaceutical Association v Pfizer Products Inc (2013 TMOB 27) reinforces the difficulty of securing registered trademark protection for marks consisting of colour applied to a pharmaceutical tablet or capsule in Canada. The case involved an opposition by the Canadian Generic Pharmaceutical Association to the registration by Pfizer Products Inc of its blue shaped tablet (VIAGRA).

In this case, the association was able to demonstrate that the colour and shape of the mark did not distinguish it from other pharmaceutical tablets and capsules, given the high number of blue pills that were actively marketed in Canada. Moreover, while the TMOB was prepared to accept that Pfizer's mark was distinctive among patients, it held that the evidence was insufficient to demonstrate that the mark was distinctive among pharmacists and physicians. Thus, the application was refused.

While the outcomes of applications to register colour tablet or capsule marks are highly dependent on the nature and extent of the evidence filed, the onus on the applicant is nevertheless significant, and invariably applications for registration of such marks are refused.


The Federal Court of Canada recently reversed the long-standing policy of the Canadian Intellectual Property Office (CIPO) regarding the registrability of sound marks in Canada. After a two-decade legal battle in which Metro-Goldwyn-Mayer (MGM) sought to register the sound of a roaring lion as a trademark, the Federal Court set aside CIPO's refusal and MGM's sound mark application issued to registration on July 31 2012. Prompted by the Federal Court decision, CIPO announced that it would accept applications to register sound marks.

The MGM decision and the resulting change in Canadian practice have brought Canada into line with many other countries that have long since recognised the registrability of sound marks. Pharmaceutical companies which use musical sounds and jingles in the branding of their products and services will no doubt welcome the shift in Canadian law and practice.

Anti-counterfeiting and enforcement

The magnitude of counterfeit pharmaceuticals in Canada remains relatively small in comparison to other industrialised countries, and there is no counterpart in Canada to the customs seizure regimes in the United States and many countries worldwide. Moreover, Canada does not have a trademark recordal regime or any other recordal regime for IP rights. Equally problematic is that customs officials in Canada will not act directly to search and seize goods independently that violate a trademark owner's rights.

The sale of counterfeit health products is governed primarily by the Customs Act, the Trademarks Act and the Copyright Act. In addition, selling counterfeit health products is a violation of the Criminal Code. However, the relevant legislation has proved difficult for rights holders to use effectively in the face of counterfeiting activities in Canada.

On October 16 2013 the Canadian government introduced Bill C-8, the Combating Counterfeit Products Act, to amend the Copyright Act and the Trademarks Act and make consequential amendments to other acts. It introduces amendments to the Copyright Act and Trademarks Act that will significantly improve border measures for counterfeit goods in Canada. (Bill C-8 was originally introduced as Bill C-56 earlier in 2013 and contains the same content).

Under Bill C-8, both the Trademarks Act and Copyright Act will be amended to include provisions that will grant the Canada Border Services Agency (CBSA) increased powers to prevent counterfeit goods from entering Canada. In addition, a copyright or registered trademark owner can file for a standing two-year request for assistance from the CBSA. During this period, the owner is provided with a sample of the goods and can request information to assist it in identifying the source of the counterfeit products. The proposed legislation also exposes offenders to fines of up to C$1 million and/or imprisonment.

The new assistance programme is available only with respect to registered trademarks and not common law trademark rights. Therefore, trademark owners would be well advised to register all marks that are potential counterfeiting targets in Canada.

This article first appeared in World Trademark Review magazine issue 47,published by The IP Media Group.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Susan Keri
Similar Articles
Relevancy Powered by MondaqAI
Smart & Biggar/Fetherstonhaugh
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Smart & Biggar/Fetherstonhaugh
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions